Can breast cancer return years later? Understanding long-term recurrence risk

New Delhi: For many women, reaching the five-year mark after breast cancer treatment feels like crossing a finish line. Appointments become less frequent, life begins to feel familiar again, and cancer gradually occupies less space in everyday thinking. Yet one question can remain: Can it come back after all these years?

The honest answer is yes. Breast cancer can recur years, sometimes decades, after the original diagnosis. But this does not mean recurrence is inevitable, nor does it mean a woman who has remained cancer-free for years should live in constant fear. It means we need to understand risk beyond the initial treatment period.

Why breast cancer can return

Cancer treatment aims to eliminate the tumour and any cancer cells that may have spread beyond it. Occasionally, a small number of cells survive treatment, remain undetectable and begin growing later. Recurrence may occur in the same breast or chest wall, in nearby lymph nodes, or at distant sites such as the bones, liver, lungs or brain.

These are clinically different situations, and the appropriate treatment depends on where the cancer returns, its biology and the treatment received previously. A cancer appearing in the opposite breast may also be a new primary cancer rather than a recurrence of the original one.

Breast cancer recurrence risk by subtype

One of the most important distinctions is the cancer’s biological subtype. Oestrogen-receptor-positive (ER-positive) breast cancers can have a prolonged risk of recurrence, even after the initial five years of endocrine therapy. Some triple-negative and other breast cancers have a different pattern, with recurrence risk often more concentrated in the earlier years.

A major analysis published in The New England Journal of Medicine examined 62,923 women with ER-positive breast cancer who were disease-free after five years of scheduled endocrine therapy. It found that distant recurrences continued between years five and 20, with risk influenced strongly by the original tumour size and lymph-node involvement. Even women with small, node-negative, low-grade tumours had a measurable late-recurrence risk. These findings describe groups of patients, not an individual’s personal prognosis. Treatment has also evolved since many participants entered the original trials.

The clinical message is clear: the passage of time matters, but so do tumour biology, stage at diagnosis, lymph-node status, grade and response to treatment. There is no single recurrence percentage that applies to every survivor.

Breast cancer follow-up after treatment

Follow-up should not become a source of endless testing, but neither should it end simply because treatment has finished. Surveillance needs to be individualised according to the original diagnosis, treatment and current health.

For women prescribed endocrine therapy, taking medication as advised is important. Tamoxifen or aromatase inhibitors may be recommended for five years or longer, depending on the individual risk-benefit assessment. Side effects should be discussed with the treating oncologist; stopping treatment independently may reduce its protective benefit. Extending therapy is not automatically right for everyone, because additional benefit must be weighed against adverse effects and quality of life.

Women should also know what changes warrant assessment. A new lump in the breast or chest wall, swelling near the collarbone or armpit, persistent unexplained bone pain, a continuing cough or breathlessness, persistent headaches, or unexplained neurological changes deserve medical attention, particularly if they are new, progressive or unexplained. These symptoms can have many causes and do not automatically indicate recurrence. The important step is to have them evaluated rather than self-diagnose or ignore them.

Routine follow-up does not usually mean repeated whole-body scans or blood tests for every person who has completed treatment. Testing should be guided by symptoms, clinical findings and established surveillance recommendations. Unnecessary investigations can create anxiety and lead to procedures that offer no proven benefit.

Breast cancer survivorship care

As a breast surgeon, I believe we must redefine what successful treatment means. Removing the tumour and completing therapy are major milestones, but good cancer care also includes a clear follow-up plan, support for treatment-related effects and guidance on when to seek help.

Women should leave active treatment knowing their cancer subtype, the reason for their prescribed medication, their follow-up schedule and whom to contact if a new concern arises. They should also be able to discuss fertility, menopause, bone health, body image and emotional wellbeing where relevant.

The purpose of long-term follow-up is not to keep a woman tied to her diagnosis. It is to help her move forward with informed confidence.

A breast cancer diagnosis may shape a chapter of life, but it should not define every chapter that follows. The goal is neither false reassurance nor lifelong fear. It is personalised care that recognises risk, responds to evidence and allows women to live fully beyond treatment.

(By Dr Jay R Anam, Breast Surgical Oncologist & Oncoplastic Breast Surgeon, SSO Cancer Hospitals)

Disclaimer: This article is based on the research and inputs shared by the doctor mentioned above and is intended for informational purposes only. The findings should not be considered medical advice or used for self-diagnosis or treatment. Consult a qualified healthcare professional for personalised guidance.